Imbruvica Approval Expanded to Include Chronic Leukemia

U.S. Food and Drug Administration approval of Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have tried at least one other anti-cancer therapy.
Source

Please follow and like us:
Facebook
Facebook
TWITTER
Visit Us
INSTAGRAM

Leave a Comment